Roche Holding (SWX:ROP) received FDA priority review for Enspryng (satralizumab) in thyroid eye disease, highlighting a potential at-home treatment option for patients. The company introduced its ...

On Tuesday, Roche Holdings AG (OTC:RHHBY) agreed to acquire Poseida Therapeutics, Inc. (NASDAQ:PSTX) for an equity value of approximately $1.5 billion on a fully diluted basis. The deal consideration ...

Roche Holding received FDA acceptance of Lunsumio VELO plus Polivy for relapsed or refractory large B cell lymphoma based on ...

Earlier today, Roche Holdings AG RHHBY announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus ...

Check out the latest Roche Holding Ag (RHHVF) stock quote and chart. View real-time stock prices & the company’s financial overview to help with your trading & investment.

Let's start with the background. Currently there are four branded and patent-protected GLP-1 weight-loss drugs on the market. Novo Nordisk owns two of them: Ozempic and Wegovy. Eli Lilly (NYSE: LLY) ...

As Novo Holdings works to lock up its Catalent purchase, the deal is attracting a steady stream of criticism from within the biopharma industry and beyond. (Stock photo/Getty Images) While Novo ...

For the second trading session in less than a week, Roche Holding (OTC: RHHBY) stock really took it on the chin Wednesday. Dispiriting news about its investigational obesity drug was the culprit; ...

Roche Holding (OTC: RHHBY) stock jumped 3.4% through 1:05 p.m. ET Monday after the pharmaceutical giant's Genentech subsidiary announced positive phase 3 clinical trial results for its fenebrutinib ...

Roche has picked a promising inflammatory bowel disease drug through its acquisition of Roivant’s Televant Holdings. In the deal Roche gains the right to develop and commercialize RVT-3101, a therapy ...

ZURICH, Oct 23 (Reuters) - Roche ROG.Son Monday said it will buy Telavant, a developer of a new treatment for inflamatory bowel diseases, for an initial $7.1 billion from American biopharma company ...